A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR)... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
12/01/2023
Locations: University of Miami, Coral Gables, Florida
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
Recruiting
This is a multi-center, randomized, two-arm study designed to measure the effectiveness of the SELENE system in reducing the number of unaddressed positive margins in breast lumpectomy procedures when used in addition to standard intraoperative margin assessment.
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Baptist MD Anderson Cancer Center, Jacksonville, Florida
Conditions: Breast Cancer
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Recruiting
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Gl... Read More
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
12/01/2023
Locations: Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida
Conditions: Anaplastic Astrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Malignant Glioma, Anaplastic Astrocytoma, Not Otherwise Specified, Glioblastoma, Not Otherwise Specified
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Recruiting
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the ef... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Baptist Md Anderson Cancer Center, Jacksonville, Florida
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Recruiting
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab. The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab (melanoma, colorectal cancer [CRC], hepatocellular carcinoma [HCC]) or of E7386 in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Florida Cancer Specialists, Fort Myers, Florida
Conditions: Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Recruiting
This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any reason are able to enter the maintenance phase of t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer
Recruiting
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: How many participants' cancers respond to vidutolimod together with cemiplimab? Is vidutolimod together with cemiplimab safe and well-tolerated? How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, particip... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: GenesisCare USA, Jacksonville, Florida
Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Triple Negative Breast Cancer, Basal Cell Carcinoma, Non-Small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Recruiting
The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to P... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Baptist MD Anderson Cancer Center ( Site 0013), Jacksonville, Florida
Conditions: Breast Neoplasms
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
All
Ages:
Between 50 years and 70 years
Trial Updated:
12/01/2023
Locations: AdventHealth Altamonte, Altamonte Springs, Florida
Conditions: Stage I Breast Cancer
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Recruiting
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
12/01/2023
Locations: Broward Health Medical Center, Fort Lauderdale, Florida
Conditions: Primary Mediastinal Large B-Cell Lymphoma
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Recruiting
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Recruiting
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida
Conditions: Stage IV Pancreatic Cancer AJCC v8, Pancreatic Adenocarcinoma